Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesStructure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 NeutralizationStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensCrystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesHuman Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic StructureFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsStructure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological TheoryLongitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodiesIsolation of monoclonal antibodies with predetermined conformational epitope specificityPre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradicationCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesDC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimersVisualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesA novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-FcComparing antigenicity and immunogenicity of engineered gp120.Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesIdentification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization.
P2860
Q24561905-896B6BF0-5CA8-4DF9-8251-E410772F4BF4Q27649247-1CACC07F-287E-4D22-91B3-5AA2A9376E77Q27650903-9B19A075-CDA2-4B88-8867-3D6F407CB00DQ27658173-EBCEC046-7926-4F92-9D6D-7960964F0651Q27666159-34CBA373-70F0-498B-AC95-B82D4E4B5EC5Q27674878-55DF9D1C-6010-4ED6-9338-B30148C1E056Q27676155-9A7DCA9E-3229-460C-A4F2-04E04059AE3FQ27677941-9C52D854-86B5-4BA8-A30F-8C70E2839FB6Q28071559-A4150C4E-4A4E-47FA-9764-A38C3C9E95E0Q28477253-918FCD13-5493-4B29-A95A-FBE1033A4586Q28728170-EE5420C5-01AE-41E1-9985-ABFAC46C44EBQ28731318-4D64E173-C5FB-41CD-98A3-8C06F97ACD2DQ28732043-3BC400BA-8F9B-4311-BA9A-1C4B845608FBQ28752503-68392BDA-FA8A-44E7-84FC-EA3165E02C1AQ29619015-DD03AA17-FF52-41F9-8BC7-8AB71D4D0442Q30472149-A88A29CD-547D-4861-B2AC-34C968C73443Q30580101-16CA84AD-C65D-41A4-AD6C-1F274948AD0CQ30603475-41D684CA-D70A-473F-B9D9-EDD77E4C3FF3Q30994182-DA6A9FAC-697E-4ABC-8D11-470BC0511BE2Q31143293-41D0EE21-C53A-489E-91B5-CC1AA2763845Q33307183-D7BA5A09-ECD4-4A3F-AC5E-4FE9273C9453Q33374701-53E42141-07BC-4092-8BE1-E63F8428DCFEQ33526340-C7F0DB60-9495-4D43-8D40-F9DBDCD87B35Q33737656-659CBF1E-B250-48D4-A822-244988B548D5Q33786222-B6955F78-BCBE-478C-A854-A26FFB23F03EQ33788810-288AE232-533F-43A6-B7E3-5C5AFA0EE268Q33984231-6899EF83-C29E-4A5C-A5FF-388E56294AA1Q33984309-B8CBA8BA-3E29-4006-A13C-91A8B248EF0FQ34083235-8703D7EB-92BE-4F05-B180-6388592CEF6FQ34085098-E56CD4A6-3E18-4CD3-AAD6-D87862E37909Q34100194-1D867F86-8C76-4F1D-B36E-5D157C062F8CQ34128200-D6B7E2E9-4A5E-417F-B7F6-0B9CC2E5C931Q34150125-CF2B3A5A-CD77-4E6C-9263-4CD77A06B9E7Q34204047-D9649C7C-3DC2-4435-8B3C-2462498BA97DQ34225659-1D5BE28F-2497-43C6-A406-B1EB90F83065Q34317025-8D39A982-083A-4A3C-9662-3DA7C2CAA333Q34392963-9B72C726-4529-439C-8704-8EBD64DFCB21Q34406977-644F9174-156A-4728-AE40-296B92877DB8Q34432690-6B409CC6-E4F2-443A-8899-A905174603B0Q34441935-50A92185-AA18-4070-AF51-FB40733792D6
P2860
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Human monoclonal antibodies sp ...... isolates from various clades.
@ast
Human monoclonal antibodies sp ...... isolates from various clades.
@en
Human monoclonal antibodies sp ...... isolates from various clades.
@nl
type
label
Human monoclonal antibodies sp ...... isolates from various clades.
@ast
Human monoclonal antibodies sp ...... isolates from various clades.
@en
Human monoclonal antibodies sp ...... isolates from various clades.
@nl
prefLabel
Human monoclonal antibodies sp ...... isolates from various clades.
@ast
Human monoclonal antibodies sp ...... isolates from various clades.
@en
Human monoclonal antibodies sp ...... isolates from various clades.
@nl
P2093
P2860
P50
P1433
P1476
Human monoclonal antibodies sp ...... y isolates from various clades
@en
P2093
Abraham Pinter
Barbara Volsky
Constance Williams
Kathy Revesz
Samuel C Kayman
Sandra Cohen
Susan Zolla-Pazner
William J Honnen
P2860
P304
P356
10.1128/JVI.76.18.9035-9045.2002
P407
P577
2002-09-01T00:00:00Z